Vir Biotechnology Prices Public Offering at $8.50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy VIR?
Source: Newsfilter
- Offering Size: Vir Biotechnology announced a public offering of 17,647,058 shares at $8.50 per share, with expected gross proceeds of $150 million, indicating strong demand in the capital markets for the company.
- Underwriter Selection: Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering, reflecting the company's focus on professionalism and reputation in selecting underwriters.
- Additional Share Option: Vir Biotechnology granted underwriters a 30-day option to purchase up to an additional 2,647,058 shares at the public offering price, providing the company with flexibility for further financing.
- Registration Statement: The offering is conducted under an automatically effective shelf registration statement on Form S-3 filed with the SEC on November 3, 2023, ensuring compliance and transparency in the issuance process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VIR
Wall Street analysts forecast VIR stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.490
Low
12.00
Averages
15.60
High
24.00
Current: 9.490
Low
12.00
Averages
15.60
High
24.00
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology announced a public offering of 17,647,058 shares at $8.50 per share, with expected gross proceeds of $150 million, indicating strong demand in the capital markets for the company.
- Underwriter Selection: Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering, reflecting the company's focus on professionalism and reputation in selecting underwriters.
- Additional Share Option: Vir Biotechnology granted underwriters a 30-day option to purchase up to an additional 2,647,058 shares at the public offering price, providing the company with flexibility for further financing.
- Registration Statement: The offering is conducted under an automatically effective shelf registration statement on Form S-3 filed with the SEC on November 3, 2023, ensuring compliance and transparency in the issuance process.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology priced its public offering at approximately 17.65 million shares of common stock at $8.50 per share, expecting gross proceeds of about $150 million, indicating the company's ability to raise capital in the market.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 2.65 million additional shares, which enhances market demand and liquidity for the stock.
- Market Reaction: Following the offering announcement, Vir Biotechnology's stock dropped 2.9% during after-market trading on Wednesday, reflecting cautious market sentiment that may impact short-term investor confidence.
- Future Outlook: The offering is expected to close on February 27, 2026, with proceeds aimed at supporting the company's $1.7 billion collaboration with Astellas, ensuring stable cash flow for the company in the coming years.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology has priced its public offering at $8.50 per share for a total of 17,647,058 shares, expecting gross proceeds of $150 million, indicating strong market demand for its equity.
- Underwriter Selection: Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering, reflecting the company's high standards in selecting financial partners to ensure a smooth fundraising process.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase an additional 2,647,058 shares, providing flexibility for further capital raising and potentially enhancing future financing capabilities.
- Compliance and Transparency: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which boosts investor confidence and may help the company attract more investments in the future.
See More
Vir Biotechnology Plans $200M Public Offering
- Funding Initiative: Vir Biotechnology has announced plans to raise $200 million through an underwritten public offering of common stock, reflecting the company's proactive approach to future funding needs aimed at supporting its R&D and operational activities.
- Additional Share Option: The company intends to grant underwriters a 30-day option to purchase up to an additional $30 million in shares, a strategy that may provide the company with greater financial flexibility to adapt to market changes.
- Market Reaction: Following the announcement of the funding plan, Vir Biotechnology's stock surged due to its collaboration agreement with Astellas, indicating market optimism regarding the company's future prospects, particularly in advancing its prostate cancer asset.
- Cash Flow Outlook: Vir Biotechnology anticipates that its $1.7 billion collaboration with Astellas will provide sufficient cash runway into Q2 2028, thereby enhancing its competitive position in the biopharmaceutical sector.
See More
Super Group and Vir Biotechnology Options Show High Trading Volume
- Super Group Options Volume: Super Group Ltd (SGHC) options are showing a trading volume of 20,737 contracts today, representing approximately 2.1 million underlying shares, which accounts for a significant 66% of SGHC's average daily trading volume of 3.1 million shares over the past month, indicating strong market interest.
- High Call Option Activity: Within SGHC, the $10.75 strike call option is particularly active, with 13,178 contracts traded today, equating to about 1.3 million shares, reflecting investor optimism regarding future price increases.
- Vir Biotechnology Options Activity: Concurrently, Vir Biotechnology Inc (VIR) options are showing a volume of 10,510 contracts today, representing approximately 1.1 million underlying shares, which is 59.4% of VIR's average daily trading volume of 1.8 million shares over the past month, demonstrating the stock's market activity.
- VIR Call Option Trading: For VIR, the $7.50 strike call option has seen a trading volume of 1,952 contracts today, representing about 195,200 shares, indicating an increasing bullish sentiment among investors regarding this stock.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology announced a public offering of 17,647,058 shares at $8.50 per share, with expected gross proceeds of $150 million, indicating strong demand in the capital markets for the company.
- Underwriter Selection: Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering, reflecting the company's focus on professionalism and reputation in selecting underwriters.
- Additional Share Option: Vir Biotechnology granted underwriters a 30-day option to purchase up to an additional 2,647,058 shares at the public offering price, providing the company with flexibility for further financing.
- Registration Statement: The offering is conducted under an automatically effective shelf registration statement on Form S-3 filed with the SEC on November 3, 2023, ensuring compliance and transparency in the issuance process.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology priced its public offering at approximately 17.65 million shares of common stock at $8.50 per share, expecting gross proceeds of about $150 million, indicating the company's ability to raise capital in the market.
- Underwriter Option: The underwriters have a 30-day option to purchase up to 2.65 million additional shares, which enhances market demand and liquidity for the stock.
- Market Reaction: Following the offering announcement, Vir Biotechnology's stock dropped 2.9% during after-market trading on Wednesday, reflecting cautious market sentiment that may impact short-term investor confidence.
- Future Outlook: The offering is expected to close on February 27, 2026, with proceeds aimed at supporting the company's $1.7 billion collaboration with Astellas, ensuring stable cash flow for the company in the coming years.
See More
Vir Biotechnology Prices Public Offering at $8.50 per Share
- Offering Size: Vir Biotechnology has priced its public offering at $8.50 per share for a total of 17,647,058 shares, expecting gross proceeds of $150 million, indicating strong market demand for its equity.
- Underwriter Selection: Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering, reflecting the company's high standards in selecting financial partners to ensure a smooth fundraising process.
- Additional Share Option: The company has granted underwriters a 30-day option to purchase an additional 2,647,058 shares, providing flexibility for further capital raising and potentially enhancing future financing capabilities.
- Compliance and Transparency: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which boosts investor confidence and may help the company attract more investments in the future.
See More
Vir Biotechnology Plans $200M Public Offering
- Funding Initiative: Vir Biotechnology has announced plans to raise $200 million through an underwritten public offering of common stock, reflecting the company's proactive approach to future funding needs aimed at supporting its R&D and operational activities.
- Additional Share Option: The company intends to grant underwriters a 30-day option to purchase up to an additional $30 million in shares, a strategy that may provide the company with greater financial flexibility to adapt to market changes.
- Market Reaction: Following the announcement of the funding plan, Vir Biotechnology's stock surged due to its collaboration agreement with Astellas, indicating market optimism regarding the company's future prospects, particularly in advancing its prostate cancer asset.
- Cash Flow Outlook: Vir Biotechnology anticipates that its $1.7 billion collaboration with Astellas will provide sufficient cash runway into Q2 2028, thereby enhancing its competitive position in the biopharmaceutical sector.
See More
Super Group and Vir Biotechnology Options Show High Trading Volume
- Super Group Options Volume: Super Group Ltd (SGHC) options are showing a trading volume of 20,737 contracts today, representing approximately 2.1 million underlying shares, which accounts for a significant 66% of SGHC's average daily trading volume of 3.1 million shares over the past month, indicating strong market interest.
- High Call Option Activity: Within SGHC, the $10.75 strike call option is particularly active, with 13,178 contracts traded today, equating to about 1.3 million shares, reflecting investor optimism regarding future price increases.
- Vir Biotechnology Options Activity: Concurrently, Vir Biotechnology Inc (VIR) options are showing a volume of 10,510 contracts today, representing approximately 1.1 million underlying shares, which is 59.4% of VIR's average daily trading volume of 1.8 million shares over the past month, demonstrating the stock's market activity.
- VIR Call Option Trading: For VIR, the $7.50 strike call option has seen a trading volume of 1,952 contracts today, representing about 195,200 shares, indicating an increasing bullish sentiment among investors regarding this stock.
See More
